NDA 006188 · Ph Health
Propylthiouracil
Propylthiouracil · Oral · Thyroid Hormone Synthesis Inhibitor
Last checked: Nov 20, 2026Latest source record: Sep 19, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1947
Jul 28, 1947
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
3 Phase 3, 0 recruiting
FAERS reports
2,081
1,801 serious, 181 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING Severe liver injury and acute liver failure, in some cases fatal, have been reported in patients treated with propylthiouracil. These reports of hepatic reactions include cases requiring liver transplantation in adult and pediatric patients. Propylthiouracil should be reserved for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism. Propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy (see Warnings and Precautions ).
What it is approved for
From the label in effect Aug 27, 2026.
INDICATIONS AND USAGE Propylthiouracil is indicated: in patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 28, 1947 Original approval
1 products under this application
- PROPYLTHIOURACIL · PROPYLTHIOURACIL 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Propylthiouracil" as an intervention, any sponsor and status, largest first.
- Thyroid Disease in Pregnancy: Case Finding Versus Universal ScreeningPivotal-lookingCompleted
Ospedale V. FazziAcademic, hospital or other
NCT00846755 · 4,657 participants · Start Mar 2005 · Primary completion Mar 2008
Drug: Levothyroxine, Propylthiouracile · For: Thyroid Disease; Pregnancy
Sites: Lecce, Italy
- Antithyroid Drug Treatment of Thyrotoxicosis in Young PeoplePivotal-lookingCompleted
Newcastle-upon-Tyne Hospitals NHS TrustAcademic, hospital or other
NCT01436994 · 81 participants · Start Jul 2004 · Primary completion Dec 2014
Drug: carbimazole; propylthiouracil and 1 more · For: Paediatric Thyrotoxicosis
Sites: Aberdeen, United Kingdom; Birmingham, United Kingdom; Cambridge, United Kingdom · 18 sites in all
- Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' OphthalmopathyPivotal-lookingStatus unknown
Medical University of ViennaAcademic, hospital or other
NCT03066076 · 60 participants (planned) · Start Mar 1, 2017 · Primary completion Feb 1, 2019
Drug: Antithyroid Drug · For: Graves Disease; Graves Ophthalmopathy; Graves' Ophthalmopathy Worsened
Sites: Vienna, Austria
Ankara UniversityAcademic, hospital or other
NCT01056419 · 40 participants (planned) · Start Jan 2009 · Primary completion Jun 2010
Drug: Propylthiouracil · For: Graves' Ophthalmopathy
Sites: Ankara, Turkey (Türkiye)
- Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of AtherosclerosisPivotal-lookingCompleted
Universitas IndonesiaAcademic, hospital or other
NCT05118542 · 36 participants · Start Jan 1, 2019 · Primary completion Jun 1, 2020
Drug: Propylthiouracil; Methimazole · For: Hyperthyroidism; Graves Disease; Atherosclerosis of Artery and 1 more
Sites: Jakarta Pusat, Indonesia
- Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKEStatus unknown
Maastricht UniversityAcademic, hospital or other
NCT05762146 · 28 participants (planned) · Start Sep 5, 2022 · Primary completion Feb 29, 2024
Drug: Riociguat; Propylthiouracil and 1 more · For: Ischemic Stroke, Acute
Sites: Essen, Germany
Dr Cipto Mangunkusumo General HospitalAcademic, hospital or other
NCT02993302 · 25 participants · Start Jul 2014 · Primary completion Mar 2015
Drug: 1α-D3; Placebos · For: Graves Disease
Maastricht UniversityAcademic, hospital or other
NCT04776499 · 8 participants · Start Mar 18, 2021 · Primary completion Feb 28, 2022
Drug: Propylthiouracil, Riociguat, Perphenazine · For: Drug Drug Interaction; Safety Issues
Sites: Heidelberg, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective198
- off label use153
- hyperthyroidism140
- foetal exposure during pregnancy119
- nausea88
- anti-neutrophil cytoplasmic antibody positive vasculitis87
- exposure during pregnancy85
- maternal exposure during pregnancy76
- hypotension71
- agranulocytosis61
- pyrexia61
- fatigue59
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 45 |
| 2005 | 39 |
| 2006 | 32 |
| 2007 | 47 |
| 2008 | 35 |
| 2009 | 30 |
| 2010 | 51 |
| 2011 | 104 |
| 2012 | 60 |
| 2013 | 47 |
| 2014 | 79 |
| 2015 | 78 |
| 2016 | 75 |
| 2017 | 72 |
| 2018 | 122 |
| 2019 | 137 |
| 2020 | 109 |
| 2021 | 97 |
| 2022 | 102 |
| 2023 | 188 |
| 2024 | 231 |
| 2025 | 205 |
| 2026 | 96 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Propylthiouracil (Propylthiouracil)
2024 spending
$2.2M
Beneficiaries
8,860
38,295 claims
Per beneficiary
$243
$0.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,365,126 |
| 2021 | $3,201,535 |
| 2022 | $3,006,140 |
| 2023 | $2,821,053 |
| 2024 | $2,154,323 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis.
Liu Y, Li Q, Xu Y, et al. · PLoS One 2023 · Meta-Analysis, Systematic Review
- Hyperthyroidism (primary).
Nygaard B · BMJ Clin Evid 2008 · Systematic Review
- Hyperthyroidism (primary).
Nygaard B · BMJ Clin Evid 2010 · Systematic Review
- Hyperthyroidism in pregnancy.
Nygaard B · BMJ Clin Evid 2015 · Systematic Review
- Bioavailability of propylthiouracil from two formulation tablets.
Gówka FK, Hermann TW, Hermann J, et al. · Pharmazie 2018 · Comparative Study, Randomized Controlled Trial
- Propylthiouracil for alcoholic liver disease.
Rambaldi A, Gluud C · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
Sponsor: Ph Health
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.